Skip to main content

Qiagen N.V. (QGEN)

NYSE: QGEN · IEX Real-Time Price · USD
53.99 0.43 (0.80%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap12.28B
Revenue (ttm)2.19B
Net Income (ttm)479.87M
Shares Out228.64M
EPS (ttm)2.05
PE Ratio26.38
Forward PE25.00
Dividendn/a
Ex-Dividend Daten/a
Volume353,234
Open53.95
Previous Close53.56
Day's Range53.63 - 54.24
52-Week Range45.33 - 59.00
Beta0.25
AnalystsBuy
Price Target56.67 (+5.0%)
Est. Earnings DateOct 26, 2021

About QGEN

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample mate...

IndustryLife Sciences Tools & Services
IPO DateJun 28, 1996
CEOThierry Bernard
Employees5,900
Stock ExchangeNYSE
Ticker SymbolQGEN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for Qiagen stock is "Buy." The 12-month stock price forecast is 56.67, which is an increase of 4.96% from the latest price.

Price Target
$56.67
(4.96% upside)
Analyst Consensus: Buy

News

QIAGEN Strengthens UK Footprint With Move to New Manchester Facilities

MANCHESTER, England & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN #manchester--QIAGEN strengthens UK footprint with move to new Manchester facilities

1 day ago - Business Wire

QIAGEN (QGEN) New Launch to Aid Global TB Elimination Targets

QIAGEN's (QGEN) QIAreach QuantiFERON-TB test is now accessible in high burden, low-resource regions.

2 days ago - Zacks Investment Research

QIAGEN N.V. to Release Results for Q3 2021 and First Nine Months of 2021

VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN N.V. to release results for Q3 2021 and first nine months of 2021

2 days ago - Business Wire

Qiagen (QGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 days ago - Zacks Investment Research

QIAGEN Launches Novel QIAreach QuantiFERON-TB Tuberculosis Test for High-Burden Regions

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #qiareach--QIAGEN launches novel QIAreach QuantiFERON-TB tuberculosis test for high-burden regions

3 days ago - Business Wire

3 Reasons Growth Investors Will Love Qiagen (QGEN)

Qiagen (QGEN) could produce exceptional returns because of its solid growth attributes.

3 days ago - Zacks Investment Research

QIAGEN (QGEN) to Report Q3 Earnings: What's in the Cards?

New product approvals, partnerships in the diagnostic solutions category and sustained success in other product areas are likely to have contributed to QIAGEN's (QGEN) growth.

4 days ago - Zacks Investment Research

QIAGEN (QGEN) to Boost NeuMoDx Production With US DOD Contract

QIAGEN's (QGEN) NeuMoDx platforms offer a unique combination of speed, flexibility, throughput and ease of use for molecular diagnostics testing, including laboratory-developed tests.

2 weeks ago - Zacks Investment Research

Qiagen Secures DoD Contract To Boost Production Capacity For NeuMoDx

Qiagen NV (NYSE: QGEN) won a U.S. government contract to increase the production capacity for consumables used on its NeuMoDx 96 and 288 integrated PCR testing systems. Related Link:   Qiagen's COVID-19...

3 weeks ago - Benzinga

QIAGEN Receives U.S. Department of Defense Contract to Further Expand Production Capacity for NeuMoDx

GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN--QIAGEN receives U.S. Department of Defense contract to further expand production capacity for NeuMoDx.

3 weeks ago - Business Wire

QGEN or ILMN: Which Is the Better Value Stock Right Now?

QGEN vs. ILMN: Which Stock Is the Better Value Option?

Other symbols:ILMN
3 weeks ago - Zacks Investment Research

3 Promising MedTech Stocks to Snap Up in Second-Half 2021

Backed by robust long-term prospects, investors can add three lucrative MedTech stocks, MMSI, ITGR and OFIX, to their watchlist.

Other symbols:ABTITGRMMSIOFIX
4 weeks ago - Zacks Investment Research

Here's Why You Should Retain QIAGEN (QGEN) Stock For Now

Investors are optimistic about QIAGEN (QGEN) owing to impressive sales of diagnostic solutions and strong international growth.

1 month ago - Zacks Investment Research

3 Diagnostics Stocks in Focus on Biden's Delta Variant Mandate

Stocks like Quest Diagnostics (DGX), Quidel Corporation (QDEL) and LabCorp (LH) are the right picks now, thanks to rising COVID-19 testing demand.

Other symbols:ABTDGXLHQDEL
1 month ago - Zacks Investment Research

QIAGEN (QGEN) to Join DAX Riding on Molecular Diagnostics Feat

QIAGEN (QGEN) is experiencing significant improvements in non-COVID areas of its molecular diagnostics portfolio.

1 month ago - Zacks Investment Research

QIAGEN to Enter the DAX – Germany's Leading Stock Market Index

VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN #dax--QIAGEN to enter the DAX – Germany's leading stock market index

1 month ago - Business Wire

QIAGEN's (QGEN) Kits Hit New Milestone for Sample Preparation

QIAGEN's (QGEN) consumables kits have been utilized to process more than 3 billion biological samples, emphasizing on its leading position in sample preparation.

1 month ago - Zacks Investment Research

QIAGEN Reaches Milestone With Its Kits Used to Process More Than Three Billion Biological Samples to Date

GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN #billions--QIAGEN reaches milestone with its kits used to process more than three billion biological samples to date

1 month ago - Business Wire

QIAGEN and GT Molecular Collaborate to Offer a Complete SARS-CoV-2 Wastewater Detection Solution Based on QIAcuity Di...

HILDEN, Germany & GERMANTOWN, Md. & FORT COLLINS, Colo.--(BUSINESS WIRE)---- $QGEN #COVID--QIAGEN and GT Molecular collaborate to offer a complete SARS-CoV-2 wastewater detection solution based on QIAcu...

2 months ago - Business Wire

Qiagen Inks Companion Diagnostic Development, Technology-Licensing Deal With OncXerna

Qiagen NV (NYSE: QGEN) and OncXerna Therapeutics have signed a master agreement to develop a next-generation sequencing (NGS) companion diagnostic for navicixizumab, which OncXerna is developing for ova...

2 months ago - Benzinga

QIAGEN and OncXerna Therapeutics Sign Licensing and Master Companion Diagnostic Agreements

HILDEN, Germany & WALTHAM, Mass. & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #cdx--QIAGEN and OncXerna Therapeutics sign licensing and master companion diagnostic agreements

2 months ago - Business Wire

QIAGEN (QGEN) Gains FDA's EUA for SARS CoV-2 Antigen Test

QIAGEN's (QGEN) QIAreach SARS CoV-2 Antigen Test can detect SARS CoV-2 antigens in 2-15 minutes and can process an average of 30 swab samples per hour.

2 months ago - Zacks Investment Research

Qiagen's COVID-19 Antigen Test Gets FDA Emergency Use Approval

The FDA has granted emergency use authorization (EUA) to Qiagen N.V.'s (NYSE: QGEN) QIAreach SARS CoV-2 Antigen Test.

2 months ago - Benzinga

QIAGEN receives U.S. FDA emergency use authorization for rapid portable test that can analyze over 30 samples per hou...

GERMANTOWN, Maryland & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN--QIAGEN receives U.S. FDA emergency use authorization for rapid portable test that can analyze over 30 samples per hour for SARS-CoV-2 a...

2 months ago - Business Wire

QIAGEN (QGEN) Q2 Earnings Top Estimates, Margins Decline

Faster-than-expected vaccination uptake leads to a reduction in demand for COVID-19 testing for QIAGEN (QGEN) in Q2.

2 months ago - Zacks Investment Research